Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4242 Campus Point Court, Suite 200 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.herontx.com |
IR: | See website |
Key People | ||
Adam Morgan Chairman of the Board | Lisa Peraza Vice President | Craig Alexander Collard Chief Executive Officer, Director |
Ira Duarte Chief Financial Officer, Principal Accounting Officer | William P. Forbes Executive Vice President, Chief Development Officer | Thomas B. Ottoboni Senior Vice President - Pharmaceutical and Translational Sciences, Chief Scientific Officer |
Sean T. Ristine Senior Vice President of Human Resources | Robert Sullivan Senior Vice President | Jason Grillot Vice President of Sales and Marketing | John Arthur Vice President - Manufacturing and Supply |
Business Overview |
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States. |
Financial Overview |
For the three months ended 31 March 2024, Heron Therapeutics Inc revenues increased 17% to $34.7M. Net loss decreased 90% to $3.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Sales and marketing - Balancing value decrease of 42% to $10.6M (expense), Labor & Related Expenses in R&D decrease of 65% to $2.5M (expense). |
Employees: | 126 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $502.06M as of Mar 31, 2024 |
Annual revenue (TTM): | $132.10M as of Mar 31, 2024 |
EBITDA (TTM): | -$79.48M as of Mar 31, 2024 |
Net annual income (TTM): | -$80.95M as of Mar 31, 2024 |
Free cash flow (TTM): | -$44.73M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $78.02M as of Mar 31, 2024 |
Shares outstanding: | 150,653,158 as of May 2, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |